CNM-Au8: Biomarker-Driven Accelerated-Approval Bid in ALS (Clene Nanomedicine) CNM-Au8 is an investigational therapy for ALS supported by FDA-recommended analyses showing significant reductions in two biomarkers of nerve injury and inflammation: neurofilament light (NfL) and glial fibrillary acidic protein (GFAP)
Yes, a split-dosing protocol (e.g., one dose in the morning, one in the evening) is an effective strategy for research on chronic conditions
Frontiers in Pharmacology, 2017, 8: 904
Bulletin of Experimental Biology and Medicine, 2003
Whether you're rehydrating after a day at Lake Skinner , recovering from an event at Town Square Park Amphitheater , or staying at a hotel near Murrieta Hot Springs , we ensure fast and reliable service